Cyclacel
Research & Development

Clinical Trials

Cyclacel Pharmaceuticals is currently evaluating the following oncology drug candidates in clinical trials:

  • CYC065: CYC065 is a highly-selective, second generation inhibitor of CDK2 and CDK9 that causes apoptotic death of cancer cells at sub-micromolar concentrations and is bioavailable via oral and intravenous routes.

    Learn more about CYC065 trial(s) on ClinicalTrials.gov

  • Sapacitabine (CYC682): sapacitabine is an orally-available nucleoside analogue with a novel mechanism; interfering with DNA synthesis by introducing single-strand DNA breaks leading to arrest of cell cycle progression in G2-phase and development of double-strand DNA breaks.

    Learn more about sapacitabine trial(s) on ClinicalTrials.gov

  • CYC140: CYC140 is a potent inhibitor of PLK-1 with high selectivity. It thwarts the dividing cells to overcome the G2/M transition that leads to apoptosis of the cells.

These candidates are experimental drugs under clinical investigation. They are not approved for human use.






 

Research & Development